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Natural killer (NK) cells are lymphocytes of the innate immune system able to kill different 
targets such as cancer cells and virally infected cells without prior activation making 
then attractive candidates for cancer immunotherapy. Umbilical cord blood (UCB) has 
become a source of hematopoietic stem cells for transplantation but as we gain a better 
understanding of the characteristics of each immune cell that UCB contains, we will 
also be able to develop new cell therapies for cancer. In this review, we present what is 
currently known of the phenotype and functions of UCB NK cells and how these cells 
could be used in the future for cancer immunotherapy.
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inTRODUCTiOn
Natural killer (NK) cells are lymphocytes of the innate immune system that exhibit cytotoxicity 
toward cancer cells and virus-infected cells and have the capacity to produce cytokines such as 
interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) in response to stimuli. NK  cells are 
defined as CD56+CD3− cells and can be divided into two main subsets according to their expression 
of CD56 and CD16. CD56dimCD16+ NK cells (CD56dim NK cells) are cytotoxic NK cells capable to 
mediate direct killing of target cells via exocytosis of granules containing granzyme B and perforin, 
activation of cell death pathways such as TRAIL or FAS/FAS-L or via antibody-dependent cellular 
cytotoxicity. CD56brightCD16−/low NK  cells (CD56bright NK  cells) are the main cytokine-producing 
NK  cells (1). In peripheral blood (PB), up to 90% of NK  cells are CD56dim NK  cells while most 
NK cells are CD56bright NK cells in lymph nodes.
Natural killer cell functions are regulated by signals delivered through activating and inhibitory 
receptors. As opposite to T cells, NK cells are “ready to go” and can eliminate target cells without 
prior stimulation. However, stimulation of NK cells by cytokines leads to NK cell activation and 
enhanced functions, in particular enhanced cytolytic activity and proliferation. NK cells have long 
been considered potential candidates for cancer immunotherapy and their versatility makes them 
attractive cells to explore. Phase I clinical trials showed autologous NK cell therapies to be feasible 
and safe without adverse effects in patients with breast cancer or non-Hodgkin’s lymphoma; however, 
these therapies had no or little impact on relapse rates (2). The potential impact of NK cell alloreactiv-
ity in hematopoietic stem cell transplantation (HSCT) was suggested by Valiante and Parham (3). 
The first evidence that allogeneic NK  cells could exert strong anti-leukemic activity and impact 
on the outcome of haploidentical transplantation stems from the study of Ruggeri et al. (4) who 
reported NK cell alloreactivity against leukemic cells while reducing the risk of graft-versus-host 
disease (GvHD) in the context of human leukocyte antigen (HLA) mismatch settings. Other trials 
FigURe 1 | Comparison of phenotypic characteristics between umbilical cord blood (UCB) natural killer (nK) cells and peripheral blood (PB) 
nK cells. In comparison to PB NK cells, UCB NK cells exhibit similar levels of CD56, NCRs (NKp46 and NKp30), and NKG2D but a lower expression of CD16, 
adhesion molecules (e.g., CD2, CD11a, CD18, CD62L), KIRs, DNAM-1, NKG2C, IL-2R, and CD57 and CD8 (receptors associated with terminal NK cell 
maturation) together with a higher expression of inhibitory receptor NKG2A indicating that UCB NK cells possess an immature phenotype and reduced 
cytotoxicity compared to PB NK cells. Further UCB NK cells have a higher expression of the bone marrow homing receptor, CXCR4, compared to PB NK cells 
proposing that cord blood NK cells may contain a greater potential to home to the bone marrow. Abbreviations: KIRs, killer-cell immunoglobulin-like receptors; 
NCRs, natural cytotoxicity receptors.
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have showed that allogeneic NK cells alone can target different 
types of cancers such as acute myeloid leukemia (AML), mela-
noma, renal cell carcinoma, Hodgkin lymphoma (5), breast and 
ovarian cancer (6), or refractory lymphoma (7). The same group 
has shown the importance of NK cell expansion in vivo, which 
can be accomplished by infusion of interleukin (IL)-2. However, 
regulatory T cells were also found to compete for this cytokine 
and beneficial effects on NK cell expansion were observed when 
regulatory T  cells could be depleted (8). Interestingly, other 
studies also have indicated that NK cell therapy could also be of 
interest to treat glioma (9) or neuroblastoma (10).
Umbilical cord blood (UCB) has become an established source 
of hematopoietic stem cells (11) for transplantation. Advantages 
for the use of UCB include low risk of viral transmission from 
donor to recipient, rapid availability of UCB units serving as an 
immediate “off-the-shelf ” product, less stringent requirements 
for HLA matching, and lower risk of GvHD. However, UCB 
contains between 10- and 100-fold fewer nucleated cells than 
other sources of HSC, limiting how many cells of interest can 
be retrieved from one UCB unit. Interestingly, NK cells are the 
first lymphocytes to recover after HSCT including after umbilical 
cord blood transplantation (UCBT) (12). In addition, NK cells are 
key effectors of the graft-versus-leukemia (GvL) effect. Especially 
after UCBT, as T cell immune reconstitution is delayed and there 
is no increased incidence of relapse, it is likely that NK cells are 
actually the main effectors of the GvL effect in the first year post-
UCBT. However, UCB also contains different types of immune 
cells including NK cells and as we learn more about their specific 
characteristics, we will identify the conditions which might ben-
efit of an UCB NK cell therapy. This review focuses on providing 
an overview of the characteristics of UCB NK cells compared to 
NK cells from PB and explain how they could be used as a cell 
therapy to cancer.
CHARACTeRiSTiCS OF UCB nK CeLLS
Natural killer cells constitute up to 10% of lymphocytes in PB 
and up to 30% in UCB (13, 14), and both CD56dim NK cells and 
CD56bright NK cells can be found in PB and UCB with some groups 
reporting similar proportions of both subsets or higher frequency 
of CD56bright NK cells in UCB (14–16). Regarding the phenotype 
and functions of UCB NK cells, some groups have identified dif-
ferences when compared to PB NK cells while others found them 
to be similar to PB NK cells (17) (Figure 1).
Advantages of UCB-Derived nK Cells
Aside from the higher percentage of NK cells present in UCB, the 
ability to cryopreserve UCB together with the ease of collecting 
UCB units offers a unique clinical advantage of making UCB an 
off-the-shelf source for NK  cell immunotherapy. Moreover, a 
more rapid recovery of NK cells was reported after UCBT than PB 
HSCT (18, 19). This faster recovery could be explained by the fact 
that UCB contains different NK cell progenitor populations that 
have the capacity to differentiate into NK cells and are typically 
absent in PB (20–22). Further, PB and UCB NK cells produced 
similar amounts of IFN-γ and TNF-α in response to different 
stimuli (14, 23) and could proliferate in response to cytokines 
such as IL-2 or IL-15 (14, 16, 24) despite UCB NK cells exhibiting 
lower expression of the IL-2 receptor subunits and lower phos-
phorylation of STAT5 (25). Additionally, UCB NK cells have also 
been described to have a higher expression of the bone marrow 
homing receptor, CXCR4, compared to PB NK cells indicating 
that UCB NK cells may contain a greater potential to home to the 
bone marrow (14). Finally, IL-15 activated UCB NK cells have 
been reported to impact positively on UCB HSC engraftment 
by enhancing their migration and clonogenic capacity, and their 
engraftment in humanized animal model (26).
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Drawbacks of UCB-Derived nK Cells
The use of cord blood (CB) as a source of NK cells for immuno-
therapy, however, is also limited as a result of the low numbers 
and immaturity of CB NK cells. Although, UCB NK cells have 
been reported to be fully mature and functional (16, 27), some 
groups found them to have an immature phenotype (14, 28), 
exhibiting normal levels of degranulation but lower cytotoxicity 
against K562 cells as compared to PB NK cells (14, 23). This lower 
activity could be explained by the fact that UCB NK cells have 
decreased expression of certain adhesion molecules on their sur-
face such as CD2, CD11a, CD18, and CD62L (15, 16), decreased 
expression of CD16 (15), decreased expression of perforin and 
granzyme B (14, 23), and lower killer-cell immunoglobulin-like 
receptors (KIRs) expression together with a higher expression 
of inhibitory molecules such as NKG2A when compared to PB 
NK cells indicating an immature phenotype (14, 23). However, 
activation with cytokines such as IL-2 or IL-15 or the combination 
of IL-15 with IL-2 or IL-18 was able to restore or enhance their 
cytotoxicity to the levels observed for PB NK cells (14, 16, 23, 25, 
29). Moreover, although the frequencies of NK cells present in 
UCB is greater than PB (14), low numbers of UCB NK cells are 
obtained as a result of the limited volume of an UCB unit, which 
is a major obstacle in obtaining sufficient numbers of NK cells 
for clinical application. However, different strategies to increase 
NK cell doses have been developed.
eXPAnSiOn OF UCB nK CeLLS
A number of studies have recently explored different platforms 
to expand UCB NK  cells. Increased NK  cell numbers can be 
achieved either by large-scale expansion techniques using 
artificial antigen-presenting cell (aAPC) or cytokines including 
IL-2, IL-15, and/or FLT-3 ligand. One such strategy employed 
to expand purified UCB-derived NK  cells on a large scale has 
been reported using good manufacturing practice (GMP)-grade 
K562-based aAPCs expressing membrane-bound IL-21 (30). 
Shah and colleagues have shown that following 14 days of culture 
in a gas permeable culture system, a 2,389-mean fold expansion 
of NK cells derived from frozen UCB was achieved. The expanded 
NK  cells presented >95% purity of CD56+CD3− NK  cells and 
displayed efficient killing capacity against multiple myeloma 
in vitro and in vivo, highlighting the use of aAPCs as an attractive 
approach to generate large numbers of functionally competent 
UCB NK  cells. A further strategy to evaluate the potential use 
of expanded NK cells was reported by using aAPCs in the form 
of genetically modified K562 cells expressing membrane-bound 
IL-15 and 41BBL (31). The aAPCs were cultured with CB mono-
nuclear cells for 7 days, which led to the generation of expanded 
UCB NK  cells that displayed increased expression of NK  cell 
activating receptors, increased perforin and granzyme expres-
sion, and increased cytotoxicity against B-cell non-Hodgkin 
lymphoma in  vitro and in  vivo. The study merits the use of 
expanded NK  cells for adoptive cellular therapy specifically to 
target relapse or refractory disease after UCBT. Finally, the use 
of irradiated Epstein–Barr virus-transformed lymphoblastoid 
cell lines and IL-2 was also recently reported to generate large 
numbers of CD56+ NK  cells derived frozen UCB (32). The 
generated NK cells exhibited higher levels of cytotoxicity against 
K562 leukemic cells than expanded PB-derived NK  cells (32). 
The unique advantage of this platform is that only 1 ml of the 
UCB unit is selectively used to generate expanded NK cells for 
adoptive therapy and the remaining UCB from the same unit can 
be cryopreserved and used for future transplantation. It would be 
interesting to assess whether the use of the same UCB for early 
NK cell adoptive therapy and transplantation can help to prevent 
relapse and augment GvL post-UCBT.
DiFFeRenTiATiOn OF nK CeLLS FROM 
UCB CD34+ CeLLS
Natural killer cells can be directly isolated from PB and UCB 
but an alternative to these cell sources is the differentiation of 
NK cells from HSC as a way to generate high numbers of cells 
(33). NK cells can be differentiated from CD34+ cells from the 
bone marrow, from embryonic stem cells, mobilized PB, or 
UCB CD34+ cells. The expansion of NK cells derived from both 
fresh and frozen UCB CD34+ cells using a cocktail of cytokines 
in a culture system has also been described as an efficient 
system to generate large numbers of NK cells. We and others 
have reported the characteristics of NK cells produced in vitro 
from UCB CD34+ cells (34–36). These cells are mostly similar 
to PB NK cells with the exception that they express low levels 
of inhibitory receptors. However, NK cells produced in such a 
way have been shown to be functional, able to kill leukemic cell 
lines and patient cells in vitro and in vivo and produce cytokines 
in response to diverse stimuli (34, 36–38). Interestingly, 
NK cells produced in vitro have been shown to expand to high 
numbers while preserving their phenotype and functions after 
cryopreservation (39). Thus, frozen UCB CD34+ cells were 
found to be the best source of NK cells when compared to fresh 
UCB-derived CD34+ cells and frozen PB CD34+ cells and could 
therefore be a readily available off-the-shelf product for NK cell 
immunotherapy.
nK Cells Alloreactivity in UCBT Setting
Umbilical cord blood NK  cells express both inhibitory and 
activating receptors, which are highly important in mediating 
self-tolerance or NK cell activity (40). Inhibitory receptors are 
part of the immunoglobulin superfamily including the KIRs, 
the immunoglobulin-like transcripts, and C-type lectin recep-
tors CD94/NKG2A. Inhibitory receptors recognize the classical 
MHC class I molecules on target cells and inhibit NK cell lysis 
(41). Most KIRs are inhibitory receptors but a limited number 
of KIRs also function as activating receptors; however, the func-
tion and ligands of the later are less well understood. Since KIR 
genes are not on the same chromosome as HLA, these genes 
are inherited independently. This allows for donor and recipi-
ent HLA-matched UCBT and mismatching between KIRs and 
their ligands, maintaining the appropriate matching required for 
HSCT but providing NK cell alloreactivity, which triggers NK cell 
activation leading to tumor cell lysis (42). This phenomenon of 
NK  cell alloreactivity was proposed as beneficial in reducing 
relapse after HSCT; however, variable results have been reported 
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from different studies (4, 43–47). In UCBT setting, only few 
studies have evaluated the outcome of UCBT using mismatched 
KIR and its ligands (48–51) with only some of them reporting 
beneficial results (52, 53). KIR haplotype has also been shown 
to influence the outcome of HSCT. In this context, the higher 
the number of activating KIR a donor has the higher NK  cell 
alloreactivity might be. Some studies have reported the beneficial 
effect of the donor B haplotype that contains more activating 
gene than a A haplotype on HSCT outcome in particular show-
ing a lower incidence of relapse for patients with AML or lower 
GvHD incidence depending on the study considered (47, 54–56). 
Whether KIR haplotype can also influence UCBT outcome needs 
to be investigated.
Finally, NK  cell licensing (57), arming/disarming (58), or 
education (59) is another factor to be considered. NK cells can 
express one or more inhibitory receptors recognizing HLA 
molecules. The process by which NK cells become functional 
and tolerant to self-HLA can be referred to as NK cell licens-
ing and is defined by the fact that to be functional NK  cells 
must express inhibitory receptors recognizing self-HLA. This 
concept has been well studied in mice and there are now also 
evidence in humans (59, 60). However, it has been reported that 
unlicensed NK  cells are able to mount an immune response 
against cytomegalovirus in mice (61) and can kill neuroblas-
toma cells in humans (10). Therefore, moving forward it will be 
essential to gain a better understanding of the impact of NK cell 
licensing on their functions especially in the context of HSCT 
including UCBT.
CURRenT CLiniCAL STUDieS invOLving 
UCB nK CeLLS
Natural killer cells can be isolated from UCB based on CD56 
purification methods. One step isolation method can be used in 
UCB as opposite to PB where two steps are needed in order to 
eliminate NKT cells. This is not necessary when considering UCB 
as it contains a very low percentage of that cell subset. In addi-
tion, UCB has the advantage of being readily available as UCB is 
cryopreserved and can be obtained from accredited UCB banks. 
Therefore, a NK cell product derived from UCB has the potential 
to be off-the-shelf. Another advantage of UCB is that HLA is less 
stringent, although it is not clear what level of matching will be 
necessary to develop a third party NK cell product from UCB. 
However, because of the limited volume of blood collected from 
the umbilical cord there are only a limited number of NK cells that 
can be isolated from UCB. In addition, as they are immature and 
have lower functionality as compared to PB NK cells; taking UCB 
NK cells to the clinics will require a prior activation/expansion 
step. Several clinical trials are currently ongoing to evaluate the 
safety and feasibility of UCB NK cells as an “off the shelf product” 
in transplant and non-transplant settings (Table 1). GMP grade 
expansion methods for UCB NK cells are currently available as 
previously described. Notably, only a handful of clinical trials 
are currently ongoing and recruiting patients using the latest 
method to expand UCB NK cells to reach the cell dose required. 
Two clinical phase I studies aim to use expanded UCB NK cells 
for the treatment of patients with chronic lymphocytic leukemia 
(NCT01619761, NCT02280525), while another aims to evaluate 
NK cell therapy in the context of autologous HSCT for patients 
with myeloma (NCT01729091).
Only a few groups have focused on developing cell therapy 
approaches based on the differentiation of NK cells from HSC 
in vitro. However, NK cells produced in vitro have been shown 
to be safe and their use feasible when considered in the context 
of allogeneic HSCT (62). In addition, another trial, oNKord®, is 
currently ongoing testing the use of NK cells produced in vitro 
from UCB CD34+ cells in patients with AML (EudraCT number 
2010-018988-41).
COnCLUDing ReMARKS
Immunotherapy is a promising treatment for different types 
of cancer allowing the possibility of personalized medicine 
for each cancer patient. UCB provides distinct advantages 
and is an increasingly attractive source for HSCT and cellular 
therapy. Despite low NK  cell numbers within a single UCB 
unit and their immature phenotype, strategies to expand 
UCB NK cells using aAPCs or cytokines and feeder cells are 
TABLe 1 | UCB nK cells currently in the clinic.
Clinical trial 
identifier
Diseases Trial 
phase
Type of transplant Conditioning Method of expansion Sponsor
NCT01619761 ALL, AML, CLL, CML, 
HL, MDS, MM, NHL, SLL
I Double umbilical cord 
blood transplantation
Fludarabin, melphalan, 
lenalidomide ± rituximab
Ex vivo expansion of NK cells 
from 20% UCB unit fraction
MD Anderson 
Cancer Center
NCT02280525 CLL, ALL, AML, CML, 
NHL, HL
I Non-HSCT Fludarabin, cyclophosphamide, 
lenalidomide, and rituximab
Ex vivo expansion of NK cells 
from thawed from UCB unit
MD Anderson 
Cancer Center
NCT01729091 MM I//II Autologous Melphalan, lenalidomide Ex vivo expansion of NK cells 
from thawed from UCB unit
MD Anderson 
Cancer Center
EudraCT number 
2010-018988-41
AML I Non-HSCT Fludarabin, cyclophosphamide NK cells generated in vitro 
from UCB progenitor cells
Radboud Medical 
Centre, Nijmegen, 
Netherlands
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CB, cord blood; CLL, chronic lymphoblastic leukemia; CML, chronic myeloid leukemia; HL, Hodgkin lymphoma; 
HSCT, hematopoietic stem cell transplantation; MDS, myelodysplastic syndromes; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; NK, natural killer; SLL, small lymphocytic 
lymphoma; UCB, umbilical cord blood.
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